drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous chimeric antigen receptor T-cell therapy: patient T cells are lentivirally transduced to express an anti-CD4 scFv derived from the humanized mAb ibalizumab, with third-generation signaling domains (CD28 and 4-1BB co-stimulation plus CD3ΞΆ activation). Administered as a single IV infusion after lymphodepleting chemotherapy. Targets CD4 on malignant cells with expected on-target depletion of normal CD4+ T cells; risks include cytokine release syndrome.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are lentivirally transduced to express an anti-CD4 chimeric antigen receptor (scFv from ibalizumab) with CD28 and 4-1BB costimulatory domains and CD3zeta activation. Upon binding CD4 on malignant cells, CAR signaling drives T-cell activation, proliferation, cytokine release, and cytotoxic killing of CD4+ tumor cells, with expected on-target depletion of normal CD4+ T cells. Administered after lymphodepleting chemotherapy.
drug_name
CD4CAR
nct_id_drug_ref
NCT06071624